BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36044719)

  • 21. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutional MLH1 methylation presenting with colonic polyposis syndrome and not Lynch syndrome.
    Kidambi TD; Blanco A; Van Ziffle J; Terdiman JP
    Fam Cancer; 2016 Apr; 15(2):275-80. PubMed ID: 26781822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.
    Poynter JN; Siegmund KD; Weisenberger DJ; Long TI; Thibodeau SN; Lindor N; Young J; Jenkins MA; Hopper JL; Baron JA; Buchanan D; Casey G; Levine AJ; Le Marchand L; Gallinger S; Bapat B; Potter JD; Newcomb PA; Haile RW; Laird PW;
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3208-15. PubMed ID: 18990764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
    Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
    Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
    Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer.
    Guyot D'Asnières De Salins A; Tachon G; Cohen R; Karayan-Tapon L; Junca A; Frouin E; Godet J; Evrard C; Randrian V; Duval A; Svrcek M; Lascols O; Vignot S; Coulet F; André T; Fléjou JF; Cervera P; Tougeron D
    ESMO Open; 2021 Jun; 6(3):100120. PubMed ID: 33930657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
    Doghri R; Houcine Y; Boujelbène N; Driss M; Charfi L; Abbes I; Mrad K; Sellami R
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):678-682. PubMed ID: 31567138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
    Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Sorscher S; Ansley K; Delaney SD; Ramkissoon S
    Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
    Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
    Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
    McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
    J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
    Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
    J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
    Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.